Cogent Biosciences Advances Bezuclastinib with Multiple Regulatory Milestones
Event summary
- Cogent submitted the SUMMIT NDA for bezuclastinib in NonAdvSM in December 2025 and expects acceptance in February 2026.
- The PEAK NDA for bezuclastinib in second-line GIST was initiated under FDA’s RTOR program, with completion on track for April 2026.
- APEX NDA submission for bezuclastinib in AdvSM is planned for the first half of 2026.
- Cogent reported $901 million in cash reserves, sufficient to fund operations into 2028.
- Six abstracts from the SUMMIT trial were accepted for presentation at the 2026 AAAAI annual meeting.
The big picture
Cogent Biosciences is positioning itself as a leader in precision therapies for KIT-mutant driven diseases with multiple regulatory milestones for bezuclastinib. The company’s strong financial position and strategic focus on expanding its pipeline underscore its ambition to become a key player in the biotech sector. The upcoming NDA submissions and potential approvals could significantly impact its market valuation and competitive standing.
What we're watching
- Regulatory Approval
- The pace at which the FDA accepts the NDAs for bezuclastinib in NonAdvSM, GIST, and AdvSM will determine Cogent’s commercial launch timeline in the second half of 2026.
- Financial Runway
- Whether Cogent’s $901 million cash reserve will be sufficient to sustain operations through 2028, especially as it prepares for multiple product launches.
- Pipeline Progress
- How the development of CGT1145 and CGT1263 will position Cogent in the competitive landscape of precision therapies for genetically defined diseases.
Related topics